BRAF mutation predicts sensitivity to MEK inhibition

Nature

Volumn 439, Issue 7074, 2006, Pages 358-362

  Solit, David B ^a   Garraway, Levi A ^b,c   Pratilas, Christine A ^a   Sawai, Ayana ^a   Getz, Gad ^c   Basso, Andrea ^a,f   Ye, Qing ^a   Lobo, Jose M ^a   She, Yuhong ^a   Osman, Iman ^d   Golub, Todd R ^b,c   Sebolt Leopold, Judith ^e   Sellers, William R ^b,c   Rosen, Neal ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e PFIZER INC   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; ENZYME KINETICS; ENZYMES; PHARMACODYNAMICS; TUMORS;

EXTRACELLULAR SIGNAL REGULATED KINASE (ERK); KINASE PATHWAY; MUTANT CELLS;

MUTAGENESIS;

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; B RAF KINASE; CYCLIN D1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; UNCLASSIFIED DRUG;

MEDICINE;

ANIMAL EXPERIMENT; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; MOUSE; MUTAGENESIS; MUTATIONAL ANALYSIS; NONHUMAN; PHARMACODYNAMICS; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALIA;

EID: 31144453233     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature04304     Document Type: Article

References (28)

1. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002).
2. Brose, M. S. et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 62, 6997-7000 (2002).
3. Gorden, A. et al. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res. 63, 3955-3957 (2003).
4. Crews, C. M., Alessandrini, A. & Erikson, R. L. The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science 258, 478-480 (1992).
5. Sebolt-Leopold, J. S. et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nature Med. 5, 810-816 (1999).
6. Ohren, J. F. et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nature Struct. Mol. Biol. 11, 1192-1197 (2004).
7. Mody, N., Leiten, J., Armstrong, C., Dixon, J. & Cohen, P. Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway. FEBS Lett. 502, 21-24 (2001).
8. Stinson, S. F. et al. Morphological and immunocytochemical characteristics of human tumour cell lines for use in a disease-oriented anticancer drug screen. Anticancer Res. 12, 1035-1053 (1992).
9. Golub, T. R. et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286, 531-537 (1999).
10. Zhao, A. et al. Resorcylic acid lactones: naturally occurring potent and selective inhibitors of MEK. J. Antibiot. (Tokyo) 52, 1086-1094 (1999).
11. Dombrowski, A. et al. Production of a family of kinase-inhibiting lactones from fungal fermentations. J. Antibiot. (Tokyo) 52, 1077-1085 (1999).
12. Chopra, A. P., Boone, S. A., Liang, X. & Duesbery, N. S. Anthrax lethal factor proteolysis and inactivation of MAPK kinase. J. Biol. Chem. 278, 9402-9406 (2003).
13. Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T. & Saltiel, A. R. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 270, 27489-27494 (1995).
14. Cheng, M., Sexl, V., Sherr, C. J. & Roussel, M. F. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc. Natl Acad. Sci. USA 95, 1091-1096 (1998).
15. Sebolt-Leopold, J. S. & Herrera, R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nature Rev. Cancer 4, 937-947 (2004).
16. Wellbrock, C. et al. V599EB-RAF is an oncogene in melanocytes. Cancer Res. 64, 2338-2342 (2004).
17. Karasarides, M. et al. B-RAF is a therapeutic target in melanoma. Oncogene 23, 6292-6298 (2004).
18. Muise-Helmericks, R. C. et al. Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J. Biol. Chem. 273, 29864-29872 (1998).
19. Diehl, J. A., Cheng, M., Roussel, M. F. & Sherr, C. J. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12, 3499-3511 (1998).
20. Filmus, J. et al. Induction of cyclin D1 overexpression by activated ras. Oncogene 9, 3627-3633 (1994).
21. Liu, J. J. et al. Ras transformation results in an elevated level of cyclin D1 and acceleration of G1 progression in NIH 3T3 cells. Mol. Cell. Biol. 15, 3654-3663 (1995).
22. Albanese, C. et al. Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J. Biol. Chem. 270, 23589-23597 (1995).
23. Aktas, H., Cai, H. & Cooper, G. M. Ras links growth factor signalling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1. Mol. Cell. Biol. 17, 3850-3857 (1997).
24. Kerkhoff, E. & Rapp, U. R. Induction of cell proliferation in quiescent NIH 3T3 cells by oncogenic c-Raf-1. Mol. Cell. Biol. 17, 2576-2586 (1997).
25. Weber, J. D., Raben, D. M., Phillips, P. J. & Baldassare, J. J. Sustained activation of extracellular-signal-regulated kinase 1 (ERK1) is required for the continued expression of cyclin D1 in G1 phase. Biochem. J. 326, 61-68 (1997).
26. Hamad, N. M. et al. Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev. 16, 2045-2057 (2002).
27. Gonzalez-Garcia, A. et al. RalGDS is required for tumour formation in a model of skin carcinogenesis. Cancer Cell 7, 219-226 (2005).
28. Garraway, L. A. et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436, 117-122 (2005).